Introduction: The Genomic/Proteomics core facility will provide support to the entire Region VIII RCE. This core will function in three broad ways: (1) the core will provide specific services that are deemed universal in terms of the development and execution of post-genomic studies. To include the development and printing of genome DMA-based microarrays, array data acquisition and analysis, DMA sequencing and proteomic support such as tandem mass spectrometry and 2-D PAGE image analysis. (2) the Genomics/Proteomics Core will provide technical assistance to investigators as needed with the design of oligonucleotides for real-time-PCR and their application, proteomic analysis via 2-D-PAGE and mass spectrometry, and high throughput production of recombinant proteins and development of purification techniques and Bioinformatics. (3) Develop new postgenomic platforms for drug screening The Genomics/Proteomics Core will support the projects of the RCE in obtaining, analyzing and interpreting post-genomic information. A central theme of this RCE proposal is to develop new vaccines, diagnostics and novel chemotherapeutics against pathogens that are bioweapon agents. This core will develop post-genomic tools and resources, and accordingly provide support to each of the research projects so that these projects may exploit current and future genomic data. Project interactions: The Post Genomics Bioinformatics Core has direct connections to proposed research plans of several RCE Nodes: II.A. Bacterial Zoonoses Disease Control and Biodefense: The Post Genomics Bioinformatics Core will support this research node by providing DMA microarrays, and performing proteomic-related mass spectrometry. The core will also assist in the validation of post-genomic data via RT-PCR and the production of recombinant products. In addition Aim 3. of the core will be integral with the development of novel inhibitors by providing HT screening on compound libraries (such as M.A.2., II.A.4.) II.B. Arboviral Disease Control and Biodefense: The major contribution to this project by the Post Genomics Bioinformatics Core is envisioned to be primarily in providing support for use of the mouse DMA microarrays, immunoregulatory DMA microarray and RT-PCR technologies. The Viral Zoonoses Program will also benefit from the production of recombinant products and mass spectrometry support (section D.1.f.). II.C. UCHSC Molecular Pathogenesis of Burkholderia Select Agents: The University of Colorado Health Sciences Project encompassing Projects II.C.1.-II.C.6. will be supported by the Post Genomics Bioinformatics Core in a similar fashion to the other projects. The core will support post-genomic studies involving DMA microarrays, molecular identification of proteins by mass spectrometry and high throughput screening. II.D. Development of Bacteriophage Amplification Reagents and Immuno-detectors for Y. pestis and F. tularensis (CSM). The Post Genomics Bioinformatics Core will provide bioinformatics support for comparative genomics and genome mining. II.G. Antiviral therapies for potential Bioterrorism Viruses (Utah State University Research Project): The Utah State University Research Project (Project II.G.2.) will obtain assistance making a VEE construct (TC-83 vaccine strain) expressing Bcl-2 gene. Other support could include whole mouse array and aspects of recombinant protein production. The cores in this RCE proposal have an integral relationship to each other. The Post Genomics Bioinformatics Core will support the Animal Core (I.B.S.a) by providing tools and reagents to help characterize the animal models of infection on the genomic scale. This support will primarily come in the form of the whole genome mouse array, the immunoregulatory direct array and the real time PCR technologies for sequence detection. In addition, work done in the Product Development and Manufacturing Core (I.B.S.b.) will benefit from the Post Genomics Bioinformatics Core facility because of the recombinant products support and mass spectrometry support.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-03
Application #
7451030
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
3
Fiscal Year
2007
Total Cost
$184,336
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:

Showing the most recent 10 out of 258 publications